

Statement under Regulation 13(3) of SEBI (Listing Obligation and disclosure Requirements) Regulations, 2015, for the quarter ended on 31st March, 2017.

Particulars	31/03/2017
Investors' Complaints	
Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed during the quarter	Nil
Remaining unsolved at the end of the quarter	Nil

For Jenburkt Pharmaceuticals Ltd.



Ashish R. Shah
Company Secretary.